$ONXX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ONYX PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ONYX PHARMACEUTICALS INC. Get notifications about new insider transactions in ONYX PHARMACEUTICALS INC for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 12 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 05 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Option Exercise | M | 12.50 | 4,000 | 50,000 | 6,000 | |
Mar 05 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Sell | S | 74.35 | 4,000 | 297,400 | 12,790 | 16.8 K to 12.8 K (-23.82 %) |
Mar 05 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Buy | M | 12.50 | 4,000 | 50,000 | 16,790 | 12.8 K to 16.8 K (+31.27 %) |
Mar 04 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Option Exercise | M | 34.48 | 10,000 | 344,800 | 53,930 | |
Mar 04 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Sell | S | 77.12 | 15,000 | 1,156,800 | 45,201 | 60.2 K to 45.2 K (-24.92 %) |
Mar 04 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Buy | M | 34.48 | 10,000 | 344,800 | 60,201 | 50.2 K to 60.2 K (+19.92 %) |
Feb 20 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Option Exercise | M | 35.18 | 3,500 | 123,130 | 15,167 | |
Feb 20 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Option Exercise | M | 26.38 | 9,480 | 250,082 | 42,312 | |
Feb 20 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Option Exercise | M | 37.68 | 3,184 | 119,973 | 30,241 | |
Feb 20 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Sell | S | 74.96 | 16,164 | 1,211,653 | 25,499 | 41.7 K to 25.5 K (-38.80 %) |
Feb 20 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Buy | M | 35.18 | 3,500 | 123,130 | 41,663 | 38.2 K to 41.7 K (+9.17 %) |
Feb 20 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Buy | M | 26.38 | 9,480 | 250,082 | 38,163 | 28.7 K to 38.2 K (+33.05 %) |
Feb 20 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Buy | M | 37.68 | 3,184 | 119,973 | 28,683 | 25.5 K to 28.7 K (+12.49 %) |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 796 | 29,993 | 30,241 | |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 583 | 21,967 | 22,167 | |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 35.18 | 802 | 28,214 | 20,855 | |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 30.28 | 656 | 19,864 | 9,188 | |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 32.07 | 1,214 | 38,933 | 20,973 | |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 77.52 | 4,051 | 314,034 | 33,833 | 37.9 K to 33.8 K (-10.69 %) |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 796 | 29,993 | 37,884 | 37.1 K to 37.9 K (+2.15 %) |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 583 | 21,967 | 37,088 | 36.5 K to 37.1 K (+1.60 %) |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 35.18 | 802 | 28,214 | 36,505 | 35.7 K to 36.5 K (+2.25 %) |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 30.28 | 656 | 19,864 | 35,703 | 35 K to 35.7 K (+1.87 %) |
Feb 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 32.07 | 1,214 | 38,933 | 35,047 | 33.8 K to 35 K (+3.59 %) |
Feb 06 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Option Exercise | M | 25.30 | 2,500 | 63,250 | 7,500 | |
Feb 06 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Sell | S | 77.29 | 2,500 | 193,225 | 8,065 | 10.6 K to 8.1 K (-23.66 %) |
Feb 06 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Buy | M | 25.30 | 2,500 | 63,250 | 10,565 | 8.1 K to 10.6 K (+31.00 %) |
Feb 06 2013 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Option Exercise | M | 37.68 | 1,250 | 47,100 | 15,800 | |
Feb 06 2013 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Option Exercise | M | 33.70 | 7,000 | 235,900 | 70,000 | |
Feb 06 2013 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Sell | S | 78.61 | 8,250 | 648,533 | 39,512 | 47.8 K to 39.5 K (-17.27 %) |
Feb 06 2013 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Buy | M | 37.68 | 1,250 | 47,100 | 47,762 | 46.5 K to 47.8 K (+2.69 %) |
Feb 06 2013 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Buy | M | 33.70 | 7,000 | 235,900 | 46,512 | 39.5 K to 46.5 K (+17.72 %) |
Feb 05 2013 | ONXX | ONYX PHARMACEUTICA ... | WIERENGA WENDALL | Director | Sell | S | 77.71 | 250 | 19,428 | 9,080 | 9.3 K to 9.1 K (-2.68 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Option Exercise | M | 34.48 | 7,112 | 245,222 | 63,930 | |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Sell | S | 85.83 | 3,299 | 283,153 | 50,201 | 53.5 K to 50.2 K (-6.17 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Sell | S | 84.41 | 6,900 | 582,429 | 53,500 | 60.4 K to 53.5 K (-11.42 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Buy | M | 34.48 | 7,112 | 245,222 | 60,400 | 53.3 K to 60.4 K (+13.35 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 37.68 | 1,438 | 54,184 | 21,562 | |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 35.18 | 3,646 | 128,266 | 13,854 | |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 30.28 | 511 | 15,473 | 8,676 | |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 28.55 | 1,027 | 29,321 | 3,213 | |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Sell | S | 85.00 | 6,622 | 562,870 | 18,219 | 24.8 K to 18.2 K (-26.66 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 37.68 | 1,438 | 54,184 | 24,841 | 23.4 K to 24.8 K (+6.14 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 35.18 | 3,646 | 128,266 | 23,403 | 19.8 K to 23.4 K (+18.45 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 30.28 | 511 | 15,473 | 19,757 | 19.2 K to 19.8 K (+2.66 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 28.55 | 1,027 | 29,321 | 19,246 | 18.2 K to 19.2 K (+5.64 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Option Exercise | M | 33.56 | 5,000 | 167,800 | 0 | |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Sell | S | 85.00 | 1,000 | 85,000 | 12,790 | 13.8 K to 12.8 K (-7.25 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Sell | S | 82.75 | 4,000 | 331,000 | 13,790 | 17.8 K to 13.8 K (-22.48 %) |
Jan 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Buy | M | 33.56 | 5,000 | 167,800 | 17,790 | 12.8 K to 17.8 K (+39.09 %) |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 2,388 | 89,980 | 31,037 | |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 1,050 | 39,564 | 22,750 | |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 35.18 | 802 | 28,214 | 21,657 | |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 30.28 | 656 | 19,864 | 9,844 | |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 32.07 | 1,344 | 43,102 | 22,187 | |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 81.99 | 1,500 | 122,985 | 33,833 | 35.3 K to 33.8 K (-4.25 %) |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 81.12 | 4,740 | 384,509 | 35,333 | 40.1 K to 35.3 K (-11.83 %) |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 2,388 | 89,980 | 40,073 | 37.7 K to 40.1 K (+6.34 %) |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 1,050 | 39,564 | 37,685 | 36.6 K to 37.7 K (+2.87 %) |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 35.18 | 802 | 28,214 | 36,635 | 35.8 K to 36.6 K (+2.24 %) |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 30.28 | 656 | 19,864 | 35,833 | 35.2 K to 35.8 K (+1.86 %) |
Jan 09 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 32.07 | 1,344 | 43,102 | 35,177 | 33.8 K to 35.2 K (+3.97 %) |
Dec 14 2012 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Sell | S | 82.25 | 7,265 | 597,546 | 4,500 | 11.8 K to 4.5 K (-61.75 %) |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 4,775 | 179,922 | 33,425 | |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 2,100 | 79,128 | 23,800 | |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 35.18 | 3,208 | 112,857 | 22,459 | |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 30.28 | 656 | 19,864 | 10,500 | |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 32.07 | 1,345 | 43,134 | 23,531 | |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 77.68 | 14,398 | 1,118,437 | 33,833 | 48.2 K to 33.8 K (-29.85 %) |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 4,775 | 179,922 | 48,231 | 43.5 K to 48.2 K (+10.99 %) |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 2,100 | 79,128 | 43,456 | 41.4 K to 43.5 K (+5.08 %) |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 35.18 | 3,208 | 112,857 | 41,356 | 38.1 K to 41.4 K (+8.41 %) |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 30.28 | 656 | 19,864 | 38,148 | 37.5 K to 38.1 K (+1.75 %) |
Dec 12 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 32.07 | 1,345 | 43,134 | 37,492 | 36.1 K to 37.5 K (+3.72 %) |
Dec 03 2012 | ONXX | ONYX PHARMACEUTICA ... | Nevinny Corinne H | Director | Sell | S | 75.00 | 3,964 | 297,300 | 7,500 | 11.5 K to 7.5 K (-34.58 %) |
Nov 30 2012 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Option Exercise | M | 34.48 | 966 | 33,308 | 71,042 | |
Nov 30 2012 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Buy | M | 34.48 | 966 | 33,308 | 53,123 | 52.2 K to 53.1 K (+1.85 %) |
Nov 30 2012 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Option Exercise | M | 37.68 | 1,250 | 47,100 | 17,050 | |
Nov 30 2012 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Option Exercise | M | 33.70 | 7,000 | 235,900 | 77,000 | |
Nov 30 2012 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Sell | S | 75.22 | 11,997 | 902,414 | 39,512 | 51.5 K to 39.5 K (-23.29 %) |
Nov 30 2012 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Buy | M | 37.68 | 1,250 | 47,100 | 51,509 | 50.3 K to 51.5 K (+2.49 %) |
Nov 30 2012 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Buy | M | 33.70 | 7,000 | 235,900 | 50,259 | 43.3 K to 50.3 K (+16.18 %) |
Nov 08 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 32.07 | 1,344 | 43,102 | 24,876 | |
Nov 08 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 30.28 | 657 | 19,894 | 11,156 | |
Nov 08 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 75.14 | 2,001 | 150,355 | 36,147 | 38.1 K to 36.1 K (-5.25 %) |
Nov 08 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 32.07 | 1,344 | 43,102 | 38,148 | 36.8 K to 38.1 K (+3.65 %) |
Nov 08 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 30.28 | 657 | 19,894 | 36,804 | 36.1 K to 36.8 K (+1.82 %) |
Nov 08 2012 | ONXX | ONYX PHARMACEUTICA ... | RINGO WILLIAM R | Director | Sell | S | 75.01 | 1,300 | 97,514 | 7,737 | 9 K to 7.7 K (-14.39 %) |
Nov 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Option Exercise | M | 37.68 | 4,775 | 179,922 | 33,425 | |
Nov 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Sell | S | 75.90 | 7,112 | 539,801 | 25,499 | 32.6 K to 25.5 K (-21.81 %) |
Nov 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Buy | M | 37.68 | 4,775 | 179,922 | 32,611 | 27.8 K to 32.6 K (+17.15 %) |
Nov 02 2012 | ONXX | ONYX PHARMACEUTICA ... | WIERENGA WENDALL | Director | Sell | S | 77.21 | 250 | 19,303 | 9,330 | 9.6 K to 9.3 K (-2.61 %) |
Oct 17 2012 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | President & CEO | Option Exercise | M | 35.18 | 39,375 | 1,385,213 | 65,625 | |
Oct 17 2012 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | President & CEO | Option Exercise | M | 29.03 | 86,224 | 2,503,083 | 13,776 | |
Oct 17 2012 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | President & CEO | Sell | S | 0.00 | 125,599 | 0 | 108,343 | 233.9 K to 108.3 K (-53.69 %) |
Oct 17 2012 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | President & CEO | Buy | M | 35.18 | 39,375 | 1,385,213 | 233,942 | 194.6 K to 233.9 K (+20.24 %) |
Oct 17 2012 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | President & CEO | Buy | M | 29.03 | 86,224 | 2,503,083 | 194,567 | 108.3 K to 194.6 K (+79.58 %) |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 28.55 | 1,321 | 37,715 | 4,240 | |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 30.28 | 1,532 | 46,389 | 9,187 | |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Sell | S | 86.95 | 2,853 | 248,068 | 18,219 | 21.1 K to 18.2 K (-13.54 %) |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 28.55 | 1,321 | 37,715 | 21,072 | 19.8 K to 21.1 K (+6.69 %) |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 30.28 | 1,532 | 46,389 | 19,751 | 18.2 K to 19.8 K (+8.41 %) |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 32.07 | 1,344 | 43,102 | 26,220 | |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 30.28 | 656 | 19,864 | 11,813 | |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 91.01 | 2,000 | 182,020 | 36,147 | 38.1 K to 36.1 K (-5.24 %) |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 32.07 | 1,344 | 43,102 | 38,147 | 36.8 K to 38.1 K (+3.65 %) |
Oct 10 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 30.28 | 656 | 19,864 | 36,803 | 36.1 K to 36.8 K (+1.81 %) |
Oct 05 2012 | ONXX | ONYX PHARMACEUTICA ... | Lasowski Juergen | EVP, Corp. Dev & St ... | Sell | S | 90.00 | 5,902 | 531,180 | 31,816 | 37.7 K to 31.8 K (-15.65 %) |
Oct 05 2012 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Sell | S | 86.51 | 2,314 | 200,184 | 43,259 | 45.6 K to 43.3 K (-5.08 %) |
Oct 04 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Sell | S | 85.08 | 2,015 | 171,436 | 27,836 | 29.9 K to 27.8 K (-6.75 %) |
Sep 06 2012 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Sell | S | 72.78 | 1,878 | 136,681 | 56,823 | 58.7 K to 56.8 K (-3.20 %) |
Aug 31 2012 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Option Exercise | M | 4.78 | 5,000 | 23,900 | 0 | |
Aug 31 2012 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Sell | S | 71.40 | 5,000 | 357,000 | 12,790 | 17.8 K to 12.8 K (-28.11 %) |
Aug 31 2012 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Buy | M | 4.78 | 5,000 | 23,900 | 17,790 | 12.8 K to 17.8 K (+39.09 %) |
Sep 11 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 32.07 | 1,345 | 43,134 | 27,564 | |
Sep 11 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 30.28 | 656 | 19,864 | 12,469 | |
Sep 11 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 77.88 | 2,001 | 155,838 | 42,397 | 44.4 K to 42.4 K (-4.51 %) |
Sep 11 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 32.07 | 1,345 | 43,134 | 44,398 | 43.1 K to 44.4 K (+3.12 %) |
Sep 11 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 30.28 | 656 | 19,864 | 43,053 | 42.4 K to 43.1 K (+1.55 %) |
Sep 06 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp, S ... | Sell | S | 72.78 | 1,721 | 125,254 | 42,397 | 44.1 K to 42.4 K (-3.90 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | Chief Financial Off ... | Option Exercise | M | 34.48 | 17,492 | 603,124 | 72,008 | |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | Chief Financial Off ... | Sell | S | 71.93 | 373 | 26,830 | 63,407 | 63.8 K to 63.4 K (-0.58 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | Chief Financial Off ... | Sell | S | 71.63 | 6,636 | 475,337 | 63,780 | 70.4 K to 63.8 K (-9.42 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | Chief Financial Off ... | Sell | S | 71.74 | 15,000 | 1,076,100 | 70,416 | 85.4 K to 70.4 K (-17.56 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | Chief Financial Off ... | Buy | M | 34.48 | 17,492 | 603,124 | 85,416 | 67.9 K to 85.4 K (+25.75 %) |
Aug 28 2012 | ONXX | ONYX PHARMACEUTICA ... | WIERENGA WENDALL | Director | Option Exercise | M | 27.14 | 5,000 | 135,700 | 0 | |
Aug 28 2012 | ONXX | ONYX PHARMACEUTICA ... | WIERENGA WENDALL | Director | Sell | S | 74.09 | 5,000 | 370,449 | 9,580 | 14.6 K to 9.6 K (-34.29 %) |
Aug 28 2012 | ONXX | ONYX PHARMACEUTICA ... | WIERENGA WENDALL | Director | Buy | M | 27.14 | 5,000 | 135,700 | 14,580 | 9.6 K to 14.6 K (+52.19 %) |
Aug 17 2012 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Option Exercise | M | 25.30 | 10,000 | 253,000 | 10,000 | |
Aug 17 2012 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Sell | S | 68.60 | 2,000 | 137,206 | 8,065 | 10.1 K to 8.1 K (-19.87 %) |
Aug 17 2012 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Sell | S | 68.63 | 10,000 | 686,322 | 10,065 | 20.1 K to 10.1 K (-49.84 %) |
Aug 17 2012 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Buy | M | 25.30 | 10,000 | 253,000 | 20,065 | 10.1 K to 20.1 K (+99.35 %) |
Aug 09 2012 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | President & CEO | Option Exercise | M | 29.03 | 250,000 | 7,257,500 | 100,000 | |
Aug 09 2012 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | President & CEO | Sell | S | 72.18 | 270,690 | 19,538,404 | 108,343 | 379 K to 108.3 K (-71.42 %) |
Aug 09 2012 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | President & CEO | Buy | M | 29.03 | 250,000 | 7,257,500 | 379,033 | 129 K to 379 K (+193.75 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Option Exercise | M | 26.38 | 12,708 | 335,237 | 51,792 | |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Option Exercise | M | 35.18 | 9,333 | 328,335 | 18,667 | |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Sell | S | 71.87 | 829 | 59,580 | 36,101 | 36.9 K to 36.1 K (-2.24 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Sell | S | 70.48 | 6,644 | 468,269 | 36,930 | 43.6 K to 36.9 K (-15.25 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Sell | S | 70.44 | 22,041 | 1,552,568 | 43,574 | 65.6 K to 43.6 K (-33.59 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Buy | M | 26.38 | 12,708 | 335,237 | 65,615 | 52.9 K to 65.6 K (+24.02 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Buy | M | 35.18 | 9,333 | 328,335 | 52,907 | 43.6 K to 52.9 K (+21.42 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | RINGO WILLIAM R | Director | Option Exercise | D | 36.61 | 7,500 | 274,575 | 12,500 | |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | RINGO WILLIAM R | Director | Option Exercise | D | 35.18 | 767 | 26,983 | 0 | |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | RINGO WILLIAM R | Director | Sell | S | 72.27 | 4,190 | 302,811 | 9,037 | 13.2 K to 9 K (-31.68 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | RINGO WILLIAM R | Director | Buy | M | 36.61 | 7,500 | 274,575 | 13,227 | 5.7 K to 13.2 K (+130.96 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | RINGO WILLIAM R | Director | Buy | M | 35.18 | 767 | 26,983 | 5,727 | 5 K to 5.7 K (+15.46 %) |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, General Counse ... | Option Exercise | M | 35.18 | 12,833 | 451,465 | 25,667 | |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, General Counse ... | Option Exercise | M | 37.68 | 2,100 | 79,128 | 25,900 | |
Aug 08 2012 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, General Counse ... | Option Exercise | M | 32.07 | 1,344 | 43,102 | 28,909 |